Integrating Network Pharmacology and Experimental Validation to Explore the Effects and Mechanisms of Qinghao Biejia Decoction and Its Active Compound Artemisinin B Against Non-Small-Cell Lung Cancer
Yonghua Ye,Yuping Yang,Li Yan,Li Zhou,Shihui Yu,Quan Du,Xiaoqiao Dong,Qiang Yuan,Letian Shan,Le Guo
DOI: https://doi.org/10.2147/dddt.s414098
2023-08-23
Abstract:Yonghua Ye, 1 Yuping Yang, 1 Li Yan, 1 Li Zhou, 2 Shihui Yu, 1 Quan Du, 3 Xiaoqiao Dong, 3 Qiang Yuan, 1 Letian Shan, 2, 4 Le Guo 1 1 College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, People's Republic of China; 2 The First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, People's Republic of China; 3 Department of Neurosurgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China; 4 Cell Resource Bank and Integrated Cell Preparation Center of Xiaoshan District, Hangzhou Regional Cell Preparation Center (Shangyu Biotechnology Co., Ltd), Hangzhou, People's Republic of China Correspondence: Letian Shan, The First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, People's Republic of China, Tel +15355015568, Email Le Guo, College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, People's Republic of China, Tel +18986648306, Email Purpose: To explore the pharmacological effects and mechanisms of Qinghao Biejia decoction (QBD) against non-small-cell lung cancer (NSCLC) based on network pharmacology and to verify the anticancer effect of artemisinin B (ART B), the active ingredient of QBD, on H1299 cells. Methods: Ultra-performance liquid chromatography coupled with quadrupole-time-of-flight mass spectrometry (UPLC-QTOF-MS/MS) was applied to explore the chemoprofile of QBD. A zebrafish xenograft model was used to determine the anti-cancer efficacy of QBD. Cell counting kit-8 assay, terminal deoxyribonucleotide transferase-mediated-dUTP nick-end labeling assay; immunofluorescence, and flow cytometry were used to evaluate the in vitro anti-proliferative and pro-apoptotic effects of QBD and ART B on H1299 cells. Subsequently, the related targets and action mechanisms of both QBD and ART B predicted by network pharmacological analyses were experimentally validated by real-time PCR and Western blot assays on H1299 cells. Results: UPLC-QTOF-MS/MS identified a total of 69 compounds (such as ART B, mangiferin, and artemisinic acid) in QBD. The in vivo data showed that QBD significantly inhibited the growth of H1299 cells in xenograft larval zebrafish from 125 to 500 μg/mL. The in vitro data showed that QBD induced apoptosis of H1299 cells, accompanied by down-regulating the expression of BCL-2 and up-regulating the expression of BIM, PUMA, BAX, c-PARP, γ-H2A.X, c-CASP3, and c-CASP8. Alike QBD, ART B exerted similar anti-proliferative and pro-apoptotic effects on H1299 cells. Moreover, ART B inhibited expressions of BCL2L1, AKT1, AKT2, MMP-2 , and EGFR , and up-regulated ALB expression. Mechanistically, ART B promoted apoptosis of H1299 cells by inhibiting PI3K/Akt signaling pathway. Conclusion: This study revealed the anti-NSCLC efficacy of QBD. ART B, the effective component of QBD, plays an anti-NSCLC role by down-regulating the PI3K-Akt signaling pathway. It suggests that QBD and ART B are promising drug candidates for NSCLC treatment. Graphical Keywords: Qinghao Biejia decoction, non-small-cell lung cancer, larval zebrafish, network pharmacology, artemisinin B Graphical Global cancer statistics in 2020 reported that lung cancer ranked at the forefront of all malignant tumors in China in terms of morbidity and mortality. The five-year survival of lung cancer in 2019 was 19.4%, and the morbidity of lung cancer has increased by 12.16% over the past decade. 1–4 Non-small-cell lung cancer (NSCLC) accounts for about 80% of all lung cancer cases, and approximately 75% of patients develop into the advanced stage. 3,5 Up to now, the current treatments of NSCLC include radiotherapy, surgical therapy, targeted therapy, and immunotherapy. 6 However, their clinical efficacy is unsatisfactory and the prognosis is poor, because of the side effects of chemotherapy and immunotherapy, drug resistance of targeted therapy, and high recurrence rate of operation, which brings great challenges to the treatment of lung cancer. 6 Traditional Chinese medicine (TCM) has a long history of treating various diseases with certain beneficial effects and few side effects, which have attracted increasing attention in recent years. 7 Qinghao Biejia decoction (QBD) is a traditional Chinese herbal prescription composed of Artemisia annua L. (Qing Hao), Carapax Amydae (Bie Jia), Anemarrhena asphodeloides Bunge (Zhi Mu), Rehmannia Glutinosa (Sheng Di), Paeonia suffruticosa Andr. (Mu Dan Pi) with effect -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal